BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call showed strong financial performance with significant revenue growth and promising drug trials. Attruby's market share is expanding, and the company has a solid cash position. Despite increased operating expenses, the focus on organic growth and potential shareholder returns is favorable. The Q&A highlighted management's confidence in sustained growth and strategic use of cash. The market cap suggests a moderate reaction, leading to a positive outlook for the stock price.
Key Financial Performance
Cash Burn Last year, we used $446 million for the year net of revenue. Cash burn declined in the fourth quarter relative to the third quarter and throughout 2025 driven by rising revenues and improving operating leverage.
Profit Projection for 2028 The company anticipates generating more than $600 million in profit in 2028, driven by growing and diversified revenue streams connected to four post Phase III assets.
Attruby Net Product Revenue (Q4 2025) $146 million, representing greater than 25% NBRx share as of December 31, 2025.
Attruby Net Product Revenue (Full Year 2025) $362.4 million, with $502.1 million in total revenue for the year. This reflects a $359.5 million increase in net product revenue from Attruby year-over-year.
Total Revenues (Q4 2025) $154.2 million, consisting of $146 million of Attruby net product revenue, $5.3 million of royalty revenue, and $2.9 million of license and service revenue. This is a $148.3 million increase compared to the same period last year.
Total Revenues (Full Year 2025) $502.1 million, compared to $221.9 million for the full year 2024. This is a $280.2 million increase year-over-year, primarily due to the increase in Attruby net product revenue.
Operating Costs and Expenses (Q4 2025) $293.7 million, a $61.8 million increase compared to the same period in the prior year, driven by a $63.3 million increase in SG&A expenses, partially offset by a $13.9 million decrease in R&D expenses.
Operating Costs and Expenses (Full Year 2025) $1 billion, a $210.6 million increase compared to the prior year, primarily driven by a $242.3 million increase in SG&A expenses, partially offset by a $54.9 million decrease in R&D expenses.
Cash Position (End of 2025) $587.5 million in cash, cash equivalents, and marketable securities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Infigratinib: Achieved positive Phase III results for achondroplasia, showing best-in-class efficacy and safety. Demonstrated significant improvements in height velocity, body proportionality, and height Z-score. Well-tolerated with no serious adverse events.
BBP-418: Positive Phase III results for LGMD2I. Full data set to be presented at the Muscular Dystrophy Association Conference. Dedicated commercial team onboarded for launch readiness.
Encaleret: Positive Phase III results for ADH1. Pre-NDA communications with the agency were supportive. Launch anticipated in late 2026 or early 2027.
Attruby: Continued strong commercial performance in ATTR cardiomyopathy. Achieved $146 million in Q4 net product revenue and $502.1 million for the year. Demonstrated rapid clinical benefit and meaningful differentiation in the market.
ATTR Cardiomyopathy: Attruby achieved significant market penetration with 7,804 unique patient prescriptions and 1,856 unique prescribers. Demonstrated strong first-line adoption and competitive differentiation.
Achondroplasia: Infigratinib's market share potential increased to over 65% peak year share due to its differentiated profile and oral administration. Expected to expand the market significantly.
LGMD2I: Efforts underway to expand awareness and accelerate diagnosis within the broader LGMD or muscular dystrophy populations.
Financial Position: Cash burn declined in Q4 2025 due to rising revenues and improving operating leverage. Ended the year with $587.5 million in cash and marketable securities.
Commercial Execution: Attruby's commercial momentum continues with strong patient persistence and adherence. Expanded sales team to support growth.
Pipeline Maturation: Transitioning from a cash-consuming to a cash-generating business by 2028, with projected profits exceeding $600 million.
Market Differentiation: Attruby positioned as a best-in-class stabilizer in ATTR cardiomyopathy, with rapid clinical benefits and competitive pricing.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tafamidis IP Uncertainty: The uncertainty surrounding the tafamidis intellectual property (IP) situation, particularly in the U.S. and Europe, poses a risk to the company's ATTR cardiomyopathy franchise. Legal trials are inherently uncertain, and potential generic entry could impact market dynamics.
Regulatory and Launch Readiness: Significant investments are required for launch readiness of new products like encaleret and BBP-418. Delays or challenges in regulatory approvals or launch execution could adversely impact timelines and financial performance.
Attruby Market Competition: Attruby faces competitive pressures from existing and emerging therapies in the ATTR cardiomyopathy market. Competitor products, such as vutrisiran, have updated safety warnings that could influence market dynamics.
Economic and Financial Risks: The company is transitioning from a cash-burning to a cash-generating business, but this transition depends on achieving projected revenues and managing cash burn effectively. Any deviation from these projections could impact financial stability.
Supply Chain and Manufacturing Risks: Potential disruptions in supply chain or manufacturing processes could impact the availability of products like Attruby and other pipeline assets.
Market Adoption and Patient Finding: The success of new product launches depends on market adoption and patient finding efforts. Failure to identify and reach target patient populations could limit revenue potential.
Clinical and Safety Risks: The success of pipeline products like infigratinib, encaleret, and BBP-418 depends on their clinical profiles and safety data. Any adverse events or safety concerns could impact market acceptance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue and Profit Projections: BridgeBio anticipates transitioning from a cash-consuming business to a cash-generating one by late 2027, with significant cash flows expected by 2028. The company projects over $600 million in profit by 2028, driven by diversified revenue streams from four post-Phase III assets.
Attruby Revenue Growth: Attruby's revenue is expected to continue growing, supported by increasing first-line adoption, new patient starts, and strong persistency and adherence. The company anticipates sustained growth in 2026.
Pipeline Launch Timelines: BridgeBio plans to launch encaleret and BBP-418 in late 2026 or early 2027, with commercial readiness activities already underway for these products.
Market Share and Expansion for Infigratinib: Infigratinib is expected to achieve a peak market share exceeding 65% in achondroplasia, with potential for significant market expansion due to its differentiated profile and oral administration.
LGMD2I Commercial Readiness: BridgeBio is preparing for the launch of BBP-418 for LGMD2I, focusing on patient identification and awareness to maximize reach upon approval.
ATTR Cardiomyopathy Franchise: Attruby is positioned as a best-in-class stabilizer for ATTR cardiomyopathy, with rapid clinical benefits and differentiation from competitors. The company remains confident in its market positioning despite potential generic competition.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why does Attruby continue to show consistent growth even as competitors' growth seems to be slowing down?
A:The growth is attributed to the strong field team at BridgeBio, category-leading efficacy and safety, and consistent results across all patient types. Additionally, there has been a second wave of prescribers responding to the product's messaging, leading to nearly 1,200 new scripts since the JPM talk.
Q:When will there be significant incremental real-world data and longer-term data for acoramidis to establish its clinical differentiation?
A:Real-world evidence is expected by the end of this calendar year. The company is also working on cardiorenal access, which could change the market landscape.
Q:What is the company's strategy for the use of cash and incremental free cash flow in the long term?
A:The company plans to reinvest in R&D, focusing on genetic diseases and partially owned assets. They may consider share buybacks or dividends if they cannot capture the NPV of fully financed assets. The focus is on organic growth rather than M&A.
Q:What are the launch readiness plans and expected field footprint for the next 12 to 18 months?
A:The company plans to launch on a global basis, building in the U.S. and ex-U.S. They aim to reset the standard of care for LGMD2I, ADH1, and other conditions with best-in-class data. Cash burn is expected to hold steady and decrease towards the end of the year due to expanding operating margins from Attruby.
Q:What are the key drivers of momentum for the company beyond 2025, and when should investors expect new assets to enter the pipeline?
A:The focus is on launching recently successful Phase III drugs, expanding indications for known safe and effective medicines, and leveraging the growing pipeline at Gondola. The company prefers organic growth and does not plan for significant M&A in the next 3-5 years.
Q:How does the company view the competitive landscape for infigratinib in achondroplasia?
A:The company believes infigratinib is best-in-class with a balance of efficacy and safety. It normalizes growth levels and avoids safety issues seen in other FGFR3 inhibitors. The company does not see a need for other FGFR3 inhibitors in achondroplasia.
Q:What is the company's perspective on the TAF IP situation and its impact on Attruby?
A:The company believes the TAF IP situation is a side issue and does not impact Attruby's uptake. Attruby's differentiated clinical data and momentum make it unlikely to be displaced by a less efficacious product, even if a generic tafamidis enters the market.
Q:What are the expectations for priority review vouchers (PRVs) as a source of non-dilutive capital?
A:The company has three programs eligible for PRVs: 418 for limb-girdle, infigratinib for achondroplasia, and the Canavan gene therapy program. PRVs are seen as significant asset value within the portfolio.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the timeline for when tafamidis might go generic in the U.S., providing only general comments on the IP situation and its potential impact. They also did not provide specific details on new assets entering the pipeline or exact timelines for real-world evidence and cardiorenal access work.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADH
Attruby BEYONTTRA
Attruby increase
Attruby stabilization
BBP
BEYONTTRA approval
EU
III study
IP
Phase III
RD activity
VYNDAMAX
achondroplasia
activity Attruby
ad
adherence
arm
baseline height
breath
capital
cash flow
change baseline
communication
decrease RD
differentiation
discontinuation event
encaleret
engine
excess
firm
importance
increase royalty
infigratinib
investment launch
pain
patient start
post Phase
revenue increase
vutrisiran
BBIO Transcript
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call showed strong financial performance with significant revenue growth and promising drug trials. Attruby's market share is expanding, and the company has a solid cash position. Despite increased operating expenses, the focus on organic growth and potential shareholder returns is favorable. The Q&A highlighted management's confidence in sustained growth and strategic use of cash. The market cap suggests a moderate reaction, leading to a positive outlook for the stock price.
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
Neutral1-12
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-10
BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call highlights strong revenue growth, promising product development, and a robust cash position. Despite increased expenses, the company maintains significant cash reserves. The Q&A reveals positive sentiment towards market dynamics and strategic positioning, with growth in patient share and prescriber engagement. Management's confidence in product efficacy and market potential further supports a positive outlook. The market cap indicates a moderate reaction, suggesting a stock price increase in the range of 2% to 8% over the next two weeks.
BBIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
